<DOC>
	<DOCNO>NCT00006280</DOCNO>
	<brief_summary>This study 's primary goal test safety effectiveness Tobramycin Inhalation ( TOBIr ) cystic fibrosis ( CF ) patient 6 month 6 year age . This drug antibiotic inhaled lung patient . It already study approved FDA treatment CF patient 6 year old . Lung fluid examine bacteria 28-day treatment . The amount bacteria treatment compare . This indicate whether antibiotic effective kill bacteria lung . Once treatment begin , patient monitor every 2 week throughout study ( 5 exams 56 day ) . Half patient receive TOBIr , half receive placebo ( substance look like TOBIr contain medication ) .</brief_summary>
	<brief_title>A Study Safety Efficacy Tobramycin Inhalation Young Children With Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<criteria>Age least 6 month le 6 year Diagnosis cystic fibrosis 2 clinical feature consistent CF confirm either sweat chloride &gt; = 60 mEq/L ( quantitative pilocarpine iontophoresis ) genotype 2 identifiable mutation consistent CF . One throat sputum microbiology culture positive Pseudomonas aeruginosa ( Pa ) within 2 week 12 month prior screen . Informed consent parent legal guardian . History adverse reaction anesthesia sedation . History aminoglycoside hypersensitivity . History unresolved anemia ( hematocrit &lt; 30 % ) thrombocytopenia ( platelet count &lt; 100,000/mm3 ) . History hemoptysis 30 day prior screen . History abnormal renal function ( serum creatinine &gt; 1.5 time upper limit normal age ) . History clinically document chronic hearing loss . Administration investigational drug within 30 day prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Cystic Fibrosis</keyword>
</DOC>